Cargando…
Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
The glutamate transporter GLT-1 is critical for the maintenance of low interstitial glutamate concentrations. Loss of GLT-1 is commonly observed in neurological disorders, including temporal lobe epilepsy (TLE). Despite the hypothesis that targeting the mechanisms of GLT-1 deficiency may be a novel...
Autores principales: | Sha, Longze, Wang, Xueqin, Li, Jing, Shi, Xinze, Wu, Liwen, Shen, Yan, Xu, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294855/ https://www.ncbi.nlm.nih.gov/pubmed/28028152 http://dx.doi.org/10.1084/jem.20160667 |
Ejemplares similares
-
Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity
por: Sha, Longze, et al.
Publicado: (2020) -
Pharmacological upregulation of GLT-1 alleviates the cognitive impairments in the animal model of temporal lobe epilepsy
por: Ramandi, Daniel, et al.
Publicado: (2021) -
Hsp90 Chaperones Bluetongue Virus Proteins and Prevents Proteasomal Degradation
por: Mohl, Bjorn-Patrick, et al.
Publicado: (2019) -
SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90
por: Lian, Bin, et al.
Publicado: (2021) -
Bacterial Hsp90 Facilitates the Degradation of Aggregation-Prone Hsp70–Hsp40 Substrates
por: Fauvet, Bruno, et al.
Publicado: (2021)